Completed PHASE1 INTERVENTIONAL 2-arm NCT02648425

Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine

Phase I Study to Evaluate the Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-Fluorouracil or Cisplatin and Capecitabine

Sponsor: ASLAN Pharmaceuticals

Conditions Solid Tumor

Interventions ASLAN001 cisplatin + 5-fluorouracil (or+ Leucovorin) cisplatin + capecitabine

Updated 9 times since 2017 Last updated: Oct 24, 2018 Started: Aug 5, 2014 Primary completion: Jun 12, 2017 Completion: Sep 15, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Solid Tumor, this trial is completed. The trial is conducted by ASLAN Pharmaceuticals and has accumulated 9 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
May 2023 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — May 2023 [monthly]

Completed PHASE1
Nov 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 4 earlier versions

Jun 2018 — Nov 2018 [monthly]

Completed PHASE1
Jan 2018 — Jun 2018 [monthly]

Completed PHASE1

Status: Recruiting → Completed
May 2017 — Jan 2018 [monthly]

Recruiting PHASE1
Jan 2017 — May 2017 [monthly]

Recruiting PHASE1

First recorded

Aug 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ASLAN Pharmaceuticals

Data source: ASLAN Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hong Kong, Hong Kong
• Taipei, Taiwan